Clinical Trial Update: Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pharmacodynamic effects of riociguat in pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Drugs mentioned

• Riociguat (riociguat)

Snippet

Sponsor: Medical University of Vienna | Conditions: Hypertension, Pulmonary, Heart Failure With Normal Ejection Fraction | Phase 2 | Status: COMPLETED